Australian digital healthcare company Eucalyptus sells for $1.6 billion in global telehealth deal

In less than a decade, Eucalyptus has gone from a Sydney startup to a $1.6 billion acquisition target.

The digital health company, best known for its weight loss brand Juniper alongside men’s and women’s health verticals, has been acquired by New York-listed telehealth group Hims & Hers Health in a blockbuster cross-border deal.

For Australia’s healthcare founders and investors, the transaction represents more than a headline valuation. It is a milestone moment for the local healthtech ecosystem and a sign that consumer-led, digitally delivered care models can scale globally.

The rise of consumer-first chronic care

Founded in 2019, Eucalyptus built condition-specific digital brands focused on areas often underserved or stigmatised in traditional healthcare settings, including weight management, sexual health and hair loss.

Its growth accelerated alongside global demand for medically supported weight loss programs, particularly those incorporating GLP-1 medications. Obesity remains one of Australia’s most pressing public health challenges, with the Australian Institute of Health and Welfare reporting that around two in three adults are overweight or obese.

Rather than positioning itself as a traditional telehealth clinic, Eucalyptus operated as a vertically integrated platform. Patients accessed online assessments, clinician oversight and prescription fulfilment through a subscription-based model. The combination of technology, logistics and strong consumer branding proved highly scalable.

Backed by major venture capital firms including Blackbird, the company expanded into international markets and built significant recurring revenue before attracting acquisition interest.

Why this deal matters

This acquisition highlights three important shifts for healthcare leaders.

• First, chronic disease management is increasingly platform-driven. Patients are seeking convenience, predictable pricing and digital access. Traditional practices now compete not only on clinical quality but on experience and accessibility.
• Second, brand has become a strategic asset in healthcare delivery. Consumer trust is no longer built solely in consulting rooms. It is shaped online, through digital touchpoints, transparency and user experience.
• Third, consolidation is accelerating. Large, publicly listed telehealth players are looking to acquire proven growth engines rather than build them from scratch. Scale, prescribing capability and supply chain integration are becoming competitive moats.

For Australian founders, the message is clear: global capital is watching this market closely.

A maturing healthtech ecosystem

Australia has long produced world-class software companies. Digital healthcare, however, has historically faced additional complexity due to regulation, prescribing frameworks and reimbursement systems.

Eucalyptus’ exit suggests those barriers are no longer insurmountable for well-capitalised, compliance-aware operators.

It also reflects the broader momentum in obesity care and preventive health investment worldwide. As governments grapple with rising chronic disease costs, private platforms that can demonstrate scalable delivery and strong patient engagement are attracting serious capital.

The bigger picture

For healthcare executives and practice owners, the implications are strategic.

Digital-first competitors are not fringe players. They are billion-dollar assets backed by global markets. The weight management boom, subscription care models and vertically integrated prescribing platforms are reshaping patient expectations.

The question is no longer whether digital care can scale. It is how traditional providers adapt, partner or differentiate in a market that is consolidating at speed.

Eucalyptus’ $1.6 billion sale signals that Australian healthcare innovation is no longer local in ambition or valuation. It is operating on the world stage.

Pictured in image: Eucalyptus co-founders.

Image source: Eucalyptus.